04.08.2021 15:30

ABL Bio Receives IND Approval for Phase 1 Clinical Trial of ABL501, an anti-LAG-3/PD-L1 Bispecific Antibody

Folgen
Werbung
  • South Korea's MFDS clears IND application for a Phase 1 study evaluating the safety and preliminary efficacy of ABL501 as a monotherapy for solid tumor treatment
  • ABL's third IND this year for bispecific antibody therapeutics

SEONGNAM, South Korea, Aug. 4, 2021 /PRNewswire/ -- ABL Bio, Inc. (KOSDAQ: 298380), a clinical-stage biotech developing bispecific antibody technology for immuno-oncology and neurodegenerative diseases, today announced that the Investigational New Drug (IND) application for ABL501 has been approved by South Korea's Ministry of Food and Drug Safety (MFDS).

The Phase 1 clinical trial is an open-label, multi-center dose escalation and dose expansion study designed to evaluate the safety, tolerability, maximum tolerated dose (MTD) and preliminary efficacy of ABL501 in patients with advanced or metastatic solid tumors.

ABL501 uses Grabody-I platform technology to simultaneously block PD-L1 and LAG-3-mediated T cell inhibition. Preclinical results demonstrate a synergistic increase of T cell activation that is higher than the enhancements induced by combination of anti-PD-L1 and LAG-3. ABL501 also showed a good safety profile in monkeys.

"LAG-3 is emerging as a promising target for cancer immunotherapy. We look forward to verifying ABL501's potential as a best-in-class bispecific antibody that overcomes the limitations of current LAG-3 targeting antibodies," said Sang Hoon Lee, Ph.D., CEO of ABL Bio. "This is already our third IND approval this year, demonstrating our strong commitment to building a robust portfolio of bispecific antibody immunotherapies. Carrying on this momentum, we expect to submit multiple additional INDs next year."

About ABL Bio

ABL Bio, Inc. (KOSDAQ: 298380) is a clinical-stage biotechnology company developing antibody therapeutics for immune-oncology and neurodegenerative diseases. With internal R&D and global partnerships, ABL has developed multiple BsAb platforms, such as 'Grabody-T,' 'Grabody-I' and 'Grabody-B' and built an innovative pipeline of multiple clinical and pre-clinical stage drug candidates. In the oncology area, we have developed Grabody-T, a modular 4-1BB engaging platform that has demonstrated superior efficacy and safety. In the neurodegenerative disorder space, we have developed Grabody-B, which is designed to maximize blood-brain barrier(BBB) penetration. Grabody-B is applicable to various CNS targets across a plethora of neurological disorders, potentially providing a breakthrough to address the high unmet medical needs in neurodegeneration. For more information, please visit www.ablbio.com

 

Jetzt kostenlos anmelden!

Das Motto "so wenig wie möglich, so viel wie nötig" kann auch im Trading funktionieren. Im Trading-Seminar jetzt live erfahren Sie, wie Sie mit nur drei Minuten pro Woche eine erfolgreiche Strategie handeln und dabei eine stabile Rendite erwirtschaften.
Jetzt kostenlos anmelden!
Werbung
Werbung
Werbung
Werbung
Börse Stuttgart Anlegerclub
Werbung

Heute im Fokus

DAX schließt mit Gewinnen -- BioNTech/Pfizer: FDA erlaubt Auffrischungsimpfung -- Deutsche Bank erwartet Ertragsrückgang in Investmentbank -- GE, Salesforce, HELLA, Lufthansa im Fokus

BP schließt einige Tankstellen in Großbritannien. Porsche SE beteiligt sich an israelischem Halbleiter-Spezialisten. Enger Zuckerberg-Vertrauter wird nächster Technologie-Chef bei Facebook. Boeing hebt 20-Jahres-Prognose für chinesischen Luftverkehrsmarkt leicht an. Deutsche Wohnen-Übernahme: Britischer Fonds will Vonovia Steine in den Weg legen. Volkswagen baut Batteriewerk in China.

Umfrage

Würden Sie es für richtig halten, wenn Gastronomie und Veranstaltungen nur noch Geimpften und Genesenen offen stehen?

finanzen.net zero
finanzen.net zero

Oskar

ETF-Sparplan

Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.
Zur klassischen Ansicht wechseln